Correlation Between Entia Biosciences and Cannabics Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Entia Biosciences and Cannabics Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entia Biosciences and Cannabics Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Entia Biosciences and Cannabics Pharmaceuticals, you can compare the effects of market volatilities on Entia Biosciences and Cannabics Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entia Biosciences with a short position of Cannabics Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entia Biosciences and Cannabics Pharmaceuticals.

Diversification Opportunities for Entia Biosciences and Cannabics Pharmaceuticals

0.0

Correlation Coefficient

Entia Biosciences  Cannabics Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between Entia and Cannabics is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Entia Biosciences and Cannabics Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cannabics Pharmaceuticals and Entia Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entia Biosciences are associated (or correlated) with Cannabics Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cannabics Pharmaceuticals has no effect on the direction of Entia Biosciences i.e., Entia Biosciences and Cannabics Pharmaceuticals go up and down completely randomly.

Pair Corralation between Entia Biosciences and Cannabics Pharmaceuticals

Given the investment horizon of 90 days Entia Biosciences is expected to generate 1.31 times less return on investment than Cannabics Pharmaceuticals. But when comparing it to its historical volatility, Entia Biosciences is 1.74 times less risky than Cannabics Pharmaceuticals. It trades about 0.07 of its potential returns per unit of risk. Cannabics Pharmaceuticals is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  1.17  in Cannabics Pharmaceuticals on October 12, 2024 and sell it today you would lose (0.17) from holding Cannabics Pharmaceuticals or give up 14.53% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	98.94%
Values	Daily Returns

Entia Biosciences  vs.  Cannabics Pharmaceuticals

Entia Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Entia Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Entia Biosciences is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Cannabics Pharmaceuticals

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Cannabics Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent fundamental drivers, Cannabics Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Entia Biosciences and Cannabics Pharmaceuticals

The main advantage of trading using opposite Entia Biosciences and Cannabics Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entia Biosciences position performs unexpectedly, Cannabics Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cannabics Pharmaceuticals will offset losses from the drop in Cannabics Pharmaceuticals' long position.

The idea behind Entia Biosciences and Cannabics Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.